2018
DOI: 10.1111/bjd.16110
|View full text |Cite
|
Sign up to set email alerts
|

Progress in the diagnosis and therapy of melanoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
3
0

Year Published

2018
2018
2025
2025

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 21 publications
0
3
0
Order By: Relevance
“…1,2 In metastatic disease, immune checkpoint inhibitors and targeted therapies have significantly improved progression-free and overall survival. 3,4 To the present date, it is almost impossible to predict which patient will benefit from a sustained treatment response. 3,4 To the present date, it is almost impossible to predict which patient will benefit from a sustained treatment response.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…1,2 In metastatic disease, immune checkpoint inhibitors and targeted therapies have significantly improved progression-free and overall survival. 3,4 To the present date, it is almost impossible to predict which patient will benefit from a sustained treatment response. 3,4 To the present date, it is almost impossible to predict which patient will benefit from a sustained treatment response.…”
Section: Introductionmentioning
confidence: 99%
“…3 However, after initial response, therapy resistances, leading to progression, are frequently observed. 3,4 To the present date, it is almost impossible to predict which patient will benefit from a sustained treatment response. Hence, novel therapy targets, prognostic and predictive markers are strongly needed to further improve melanoma treatment.…”
Section: Introductionmentioning
confidence: 99%
“…several therapeutic agents have been recently approved (Leonardi et al, 2018;Malas et al, 2014;Ross & Gershenwald, 2011). Despite progress in advanced malignant melanoma therapy, the patient prognosis remains poor (Wiesner & Zbyszewski, 2018). The identification of reliable biomarkers represents therefore a primary goal.…”
mentioning
confidence: 99%